An observational study in Parkinsonian Syndromes, Parkinson's Disease and Multiple System Atrophy, sponsored by University Hospital, Bordeaux. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-31.
Sponsored by University Hospital, Bordeaux · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Parkinson Disease by University Hospital, Bordeaux — 4 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · University Hospital, Bordeaux.
Among the 14 studies in Parkinson Disease by University Hospital, Bordeaux, this one is one of 2 that started in 2013, is one of 2 observational ones, and was the 4th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →4 of the 14 studies in Parkinson Disease by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Bordeaux · Sites in France
Ages 18–75
University Hospital, Bordeaux · Sites in France
Ages 18–75
University Hospital, Bordeaux · Sites in France
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2013.
This study's planned enrollment of 100 is close to the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Median enrollment 31 across the 12 interventional studies, 65 across the 2 observational. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
2 of the studies in Parkinson Disease by University Hospital, Bordeaux that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06241924University Hospital, BordeauxOscillatory Activity in Basal Ganglia Circuits During Normal and Pathological Movement | 2027-02-05 |
| NCT06438419University Hospital, BordeauxParkinsonism-Related Oscillations in the Cortico-Basal Ganglia-Thalamic Network During Movement: Beyond the Frequency Range | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Parkinson Disease by University Hospital, Bordeaux, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Parkinson disease (PD), multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are neurodegenerative disorders. PD and MSA are alpha-synucleinopathies, which are characterized by the abnormal accumulation of alpha-synuclein, while tau protein accumulates in PSP. The development of biological markers for the diagnosis and prognosis in PD, MSA and PSP remains an unmet need. Such biological markers are crucial for future disease-modification and neuroprotection trials. Alpha-synuclein has a high potential for biomarker development since it constitutes the pathological hallmark feature in PD and MSA. The oligomeric alpha-synuclein seems to be particularly involved in abnormal protein aggregation in alpha-synucleinopathies.
The main objective is to compare oligomeric alpha-synuclein CSF levels between PD, MSA and PSP patients. PD and MSA patients will receive Cerebrospinal Fluid (CSF) and blood sampling at two study visits (baseline and after 12 months). Major secondary objectives are (i) to assess potential associations between the biomarker and clinical measures of disease severity and progression in MSA and PSP, and (ii) to assess the variation of the biomarker and its correlation to disease severity and progression in PD, MSA and PSP.
The differential diagnosis between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy can be very difficult in early disease. PD, MSA and PSP are neurodegenerative disorders. PD and MSA belong to the alpha-synucleinopathies, which are characterized by the abnormal accumulation of alpha-synuclein. Alpha-synuclein accumulates in intraneuronal Lewy bodies in PD patients and as intracytoplasmic glial inclusions in MSA. In PSP, tau protein accumulates in neurons and glia cells while alpha-synuclein deposits are only found to a small extend.
The development of biological markers for the diagnosis and prognosis of PD, MSA and PSP remains an unmet need. Beyond guiding clinical decision-making, such biological markers are crucial for future disease-modification and neuroprotection trials.
Alpha-synuclein has a high potential for biomarker development since it constitutes the pathological hallmark feature of PD and MSA. The oligomeric alpha-synuclein fraction whose CSF levels are increased in PD seems to be particularly involved in abnormal protein aggregation in alpha-synucleinopathies.
The main objective of the study is to compare oligomeric alpha-synuclein CSF levels between PD, MSA and PSP patients. Secondary objectives are (i) to compare total alpha-synuclein levels and the index total/oligomeric alpha-synuclein between PD, MSA and PSP, (ii) to study the correlation and concordance between CSF and plasma levels of total and oligomeric alpha-synuclein, (iii) to assess potential associations between the biomarker and clinical measures of disease severity and progression and (iv) to assess the variation of the biomarker over time and its correlation to disease severity and progression.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
This study's planned enrollment of 100 is close to the median of 96 across 1,088 observational studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
Compared within Parkinson Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Parkinsonian Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients suffering from parkinson disease or multiple system atrophy or progressive supranuclear palsy.
Patients receiving anticoagulants, showing abnormal coagulation on blood testing or thrombocytopenia are excluded from this study.
Patients showing more than 500 erythrocytes per mm3 of LCR are excluded from this study.
PD patients
inclusion criteria:
exclusion criteria:
MSA patients
inclusion criteria:
exclusion criteria:
PSP patients
inclusion criteria:
exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients suffering from Parkinson desease
Other: clinical measures of disease severity and progression
Patients suffering from "probable" multiple system atrophy according to clinical consensus criteria and age \> 30
Other: CSF, blood and urine sampling · Other: clinical measures of disease severity and progression
Patients suffering from progressive supranuclear palsy and age \> 40
Other: CSF, blood and urine sampling · Other: clinical measures of disease severity and progression
PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).
Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
Concentration of oligomeric alpha-synuclein in cerebrospinal fluid
Time frame: at day 0 (inclusion) and one year after inclusion
Total alpha-synuclein concentration in CSF, oligomeric/total alpha-synuclein ratio in CSF
Time frame: At inclusion (Day 0) and one year after inclusion
Oligomeric and total alpha-synuclein concentration in plasma, oligomeric/total alpha-synuclein ratio in plasma
Time frame: At inclusion (Day 0) and one year after inclusion
Alpha-synuclein levels in relation to disease severity and progression, disease duration and age
Time frame: At inclusion (Day 0) and one year after inclusion
Variation of alpha-synuclein levels between first and second sampling
Time frame: At inclusion (Day 0) and one year after inclusion
Started Dec 2013 (actual). Primary completion is estimated for Dec 2023, 120 months after the start.
Of 381 non-industry observational studies under Parkinson Disease, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 133. This study's planned 120 months is above that.
Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →